Rendering

Component: (Network and Table)
Network
033 - Disclosure - Note 13 - Business Segment, Geographic and Concentration Risk Information (Tables)
(http://nuvectramedical.com/20161230/role/statement-note-13-business-segment-geographic-and-concentration-risk-information-tables)
TableStatement [Table]
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001648893 (http://www.sec.gov/CIK)
Scenario [Axis]Scenario, Unspecified [Domain]
Statement [Line Items]Period [Axis]
2016-01-02 - 2016-12-30
Notes Tables
 
Revenue from External Customers by Products and Services [Table Text Block]
 
 
Year Ended
 
 
 
December 30,
2016
 
 
January 1,
2016
 
Product line sales:
                
Neural interface components and systems
   $
5,152
     $
3,920
  
Algovita
    
4,162
      
1,318
  
Development and engineering service
    
3,221
      
—
  
Total sales
   $
12,535
     $
5,238
  
  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
 
 
Year Ended
 
 
 
December 30,
2016
 
 
January 1,
2016
 
Business segment sales:
                
Nuvectra
   $
7,383
     $
1,318
  
NeuroNexus
    
5,152
      
3,920
  
Total sales
   $
12,535
     $
5,238
  
 
 
Year Ended
 
 
 
December 30,
2016
 
 
January 1,
2016
 
Segment loss from operations:
                
Nuvectra
   $
(37,702
)
   $
(23,452
)
NeuroNexus
    
300
      
(964
)
Total segment loss from operations
    
(37,402
)
    
(24,416
)
Unallocated operating expenses
    
—
      
—
  
Operating loss
    
(37,402
)
    
(24,416
)
Unallocated other income (expense), net
    
(1,026
)
    
—
  
Loss before provision for income taxes
   $
(38,428
)
   $
(24,416
)
 
 
Year Ended
 
 
 
December 30,
2016
 
 
January 1,
2016
 
Depreciation and amortization:
                
Nuvectra
   $
1,908
     $
257
  
NeuroNexus
    
335
      
330
  
Total depreciation and amortization included in segment income from operations
    
2,243
      
587
  
Unallocated depreciation and amortization
    
—
      
—
  
Total depreciation and amortization
   $
2,243
     $
587
  
 
 
Year Ended
 
 
 
December 30,
2016
 
 
January 1,
2016
 
Expenditures for tangible long-lived assets:
                
Nuvectra
   $
3,950
     $
511
  
NeuroNexus
    
81
      
18
  
Total reportable segments
    
4,031
      
529
  
Unallocated tangible long-lived assets
    
—
      
—
  
Total expenditures
   $
4,031
     $
529
  
 
 
At
 
 
 
December 30,
2016
 
 
January 1,
2016
 
Identifiable assets:
                
Nuvectra
   $
111,503
     $
37,762
  
NeuroNexus
    
7,799
      
7,636
  
Total reportable segments
    
119,302
      
45,398
  
Unallocated assets
    
—
      
—
  
Total assets
   $
119,302
     $
45,398
  
  
Revenue from External Customers by Geographic Areas [Table Text Block]
 
 
Year Ended
 
 
 
December 30,
2016
 
 
January 1,
2016
 
Sales by geographic area:
                
United States
   $
5,800
     $
2,060
  
Non-Domestic locations:
                
Switzerland
    
3,461
      
83
  
Germany
    
1,567
      
1,668
  
Rest of world
    
1,707
      
1,427
  
                 
Total sales
   $
12,535
     $
5,238